What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
BACKGROUND:It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some guidelines suggest stopping apparently ineffective therapy, but no studies have addr...
المؤلفون الرئيسيون: | McGovern, A, Dennis, J, Shields, B, Hattersley, A, Pearson, E, Jones, A, Mastermind Consortium |
---|---|
مؤلفون آخرون: | Farmer, A |
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
BioMed Central
2019
|
مواد مشابهة
-
What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
حسب: Andrew P. McGovern, وآخرون
منشور في: (2019-04-01) -
Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?
حسب: Angus G Jones, وآخرون
منشور في: (2016-01-01) -
Costs and treatment pathways for type 2 diabetes in the UK: a Mastermind Cohort study
حسب: Eibich, U, وآخرون
منشور في: (2017) -
Mastermind ophthalmology
حسب: Madhav
منشور في: (2007-01-01) -
Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
حسب: Agbaje, O, وآخرون
منشور في: (2017)